COMP <GO>
ALNY vs VTRS // OPERATING MARGIN
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Viatris Inc. (NASDAQ) • 15-METRIC TALLY: ALNY 8
— VTRS 4
▲ OPERATING MARGIN LEADER: ALNY
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
operating-margins
13.50%
LAST: $18.67 (-1.92%) • MKT CAP: $21.86B
operating-margins
-18.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. VTRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | VTRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 35.20% | +46.60 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | -8.10% | +29.40 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 8.78% | -6.78 | VTRS | /fcf-yield <GO> |
| Operating Margin ACTIVE | 13.50% | -18.70% | +32.20 | ALNY | /operating-margins <GO> |
| Net Profit Margin | 8.40% | -14.60% | +23.00 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | -3.00% | +68.20 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 0.81 | +2.35 | ALNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.8 | 62.5 | -36.70 | VTRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 33.0x | +29.30 | VTRS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.10B | $21.86B | $236.3M | ALNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | VTRS REV | ALNY GROSS % | VTRS GROSS % | ALNY FCF | VTRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $14.25B | 81.8% | 35.2% | $465.4M | $1.94B |
| FY 2024 | $2.25B | $14.69B | 86.4% | 38.3% | -$42.6M | $1.98B |
| FY 2023 | $1.83B | $15.39B | — | — | $21.9M | $2.21B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
VTRS // BETA 1.15